Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Assets: 2022-2024

Historic Assets for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $160.4 million.

  • Taysha Gene Therapies' Assets rose 75.65% to $316.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.6 million, marking a year-over-year increase of 75.65%. This contributed to the annual value of $160.4 million for FY2024, which is 7.16% down from last year.
  • As of FY2024, Taysha Gene Therapies' Assets stood at $160.4 million, which was down 7.16% from $172.7 million recorded in FY2023.
  • Taysha Gene Therapies' 5-year Assets high stood at $172.7 million for FY2023, and its period low was $126.3 million during FY2022.
  • Its 3-year average for Assets is $153.1 million, with a median of $160.4 million in 2024.
  • Its Assets has fluctuated over the past 5 years, first spiked by 36.79% in 2023, then fell by 7.16% in 2024.
  • Over the past 3 years, Taysha Gene Therapies' Assets (Yearly) stood at $126.3 million in 2022, then skyrocketed by 36.79% to $172.7 million in 2023, then fell by 7.16% to $160.4 million in 2024.